Impact of Candida auris on Critically Ill Patients: A Three-Year Observational Study in a Greek Intensive Care Unit
Abstract
:1. Introduction
2. Materials and Methods
2.1. Setting
2.2. Definitions of Cases and Collection of Clinical Data
2.3. Environmental Sampling
2.4. Identification of Isolates and Antifungal Susceptibility Testing
2.5. Statistical Analysis
3. Results
3.1. Patients’ Characteristics—Host Risk Factors (Table 1)
3.2. Timeline of Cases
3.3. Microbiological Data and Antifungal Susceptibility Testing
3.4. Therapeutic Strategies and Outcome Analysis
4. Discussion
5. Limitations—Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Satoh, K.; Makimura, K.; Hasumi, Y.; Nishiyama, Y.; Uchida, K.; Yamaguchi, H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 2009, 53, 41–44. [Google Scholar] [CrossRef] [PubMed]
- Chowdhary, A.; Sharma, C.; Meis, J.F. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017, 13, e1006290. [Google Scholar] [CrossRef]
- Chowdhary, A.; Voss, A.; Meis, J.F. Multidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections? J. Hosp. Infect. 2016, 94, 209–212. [Google Scholar] [CrossRef]
- Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.; Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 2017, 64, 134–140. [Google Scholar] [CrossRef] [PubMed]
- Suphavilai, C.; Ko, K.K.K.; Lim, K.M.; Tan, M.G.; Boonsimma, P.; Chu, J.J.K.; Goh, S.S.; Rajandran, P.; Lee, L.C.; Tan, K.Y.; et al. Detection and characterisation of a sixth Candida auris clade in Singapore: A genomic and phenotypic study. Lancet Microbe 2024, 5, 100878. [Google Scholar] [CrossRef]
- Chow, N.A.; Muñoz, J.F.; Gade, L.; Berkow, E.L.; Li, X.; Welsh, R.M.; Forsberg, K.; Lockhart, S.R.; Adam, R.; Alanio, A.; et al. Tracing the evolutionary history and global expansion of Candida auris using population genomic analyses. mBio 2020, 11, e03364-19. [Google Scholar] [CrossRef] [PubMed]
- Vallabhaneni, S.; Kallen, A.; Tsay, S.; Chow, N.; Welsh, R.; Kerins, J.; Kemble, S.K.; Pacilli, M.; Black, S.R.; Landon, E.; et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013–August 2016. Am. J. Transplant. 2017, 17, 296–299. [Google Scholar] [CrossRef]
- Bing, J.; Du, H.; Guo, P.; Hu, T.; Xiao, M.; Lu, S.; Nobile, C.J.; Chu, H.; Huang, G. Candida auris-associated hospitalizations and outbreaks, China, 2018–2023. Emerg. Microbes Infect. 2024, 13, 2302843. [Google Scholar] [CrossRef]
- Lee, W.G.; Shin, J.H.; Uh, Y.; Kang, M.G.; Kim, S.H.; Park, K.H.; Jang, H.-C. First three reported cases of nosocomial fungemia caused by Candida auris. J. Clin. Microbiol. 2011, 49, 3139–3142. [Google Scholar] [CrossRef] [PubMed]
- Farooqi, J.Q.; Jabeen, K.; Saeed, N.; Iqbal, N.; Malik, B.; Lockhart, S.R.; Zafar, A.; Brandt, M.E.; Hasan, R. Invasive candidiasis in Pakistan: Clinical characteristics, species distribution and antifungal susceptibility. J. Med. Microbiol. 2013, 62, 259–268. [Google Scholar] [CrossRef]
- Pfaller, M.A.; Diekema, D.J.; Turnidge, J.D.; Castanheira, M.; Jones, R.N. Twenty years of the SENTRY antifungal surveillance program: Results for Candida species from 1997–2016. Open Forum Infect. Dis. 2019, 6, S79–S94. [Google Scholar] [CrossRef] [PubMed]
- Kean, R.; Ramage, G. Combined antifungal resistance and biofilm tolerance: The global threat of Candida auris. mSphere 2019, 4, e00458-19. [Google Scholar] [CrossRef] [PubMed]
- Welsh, R.M.; Bentz, M.L.; Shams, A.; Houston, H.; Lyons, A.; Rose, L.J.; Litvintseva, A.P. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J. Clin. Microbiol. 2017, 55, 2996–3005. [Google Scholar] [CrossRef]
- Cosio, T.; Pica, F.; Fontana, C.; Pistoia, E.S.; Favaro, M.; Valsecchi, I.; Zarabian, N.; Campione, E.; Botterel, F.; Gaziano, R. Stephanoascus ciferrii Complex: The Current State of Infections and Drug Resistance in Humans. J. Fungi 2024, 10, 294. [Google Scholar] [CrossRef]
- Magrì, C.; De Carolis, E.; Ivagnes, V.; Di Pilato, V.; Spruijtenburg, B.; Marchese, A.; Meijer, E.F.J.; Chowdhary, A.; Sanguinetti, M. “CLADE-FINDER”: Candida auris Lineage Analysis Determination by Fourier Transform Infrared Spectroscopy and Artificial Neural Networks. Microorganisms 2024, 12, 2153. [Google Scholar] [CrossRef]
- Zhu, Y.; O’Brien, B.; Leach, L.; Clarke, A.; Bates, M.; Adams, E.; Ostrowsky, B.; Quinn, M.; Dufort, E.; Southwick, K.; et al. Laboratory analysis of an outbreak of Candida auris in New York from 2016 to 2018: Impact and lessons learned. J. Clin. Microbiol. 2020, 58, e01503–e01519. [Google Scholar] [CrossRef] [PubMed]
- Eyre, D.W.; Sheppard, A.E.; Madder, H.; Moir, I.; Moroney, R.; Quan, T.P.; Griffiths, D.; George, S.; Butcher, L.; Morgan, M.; et al. A Candida auris outbreak and its control in an Intensive Care Setting. N. Engl. J. Med. 2018, 379, 1322–1331. [Google Scholar] [CrossRef]
- Edwards, J.E., Jr.; Dolin, R.; Blaser, M.J. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th ed.; Elsevier: Philadelphia, PA, USA, 2015; pp. 2879–2894. [Google Scholar]
- Kathuria, S.; Singh, P.K.; Sharma, C.; Prakash, A.; Masih, A.; Kumar, A.; Meis, J.F.; Chowdhary, A. Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J. Clin. Microbiol. 2015, 53, 1823–1830. [Google Scholar] [CrossRef]
- Borman, A.M.; Szekely, A.; Johnson, E.M. Comparative Pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere 2016, 1, e00189-16. [Google Scholar] [CrossRef]
- Kim, T.-H.; Kweon, O.J.; Kim, H.R.; Lee, M.-K. Identification of uncommon Candida species using commercial identification systems. J. Microbiol. Biotechnol. 2016, 26, 2206–2213. [Google Scholar] [CrossRef]
- Kordalewska, M.; Zhao, Y.; Lockhart, S.R.; Chowdhary, A.; Berrio, I.; Perlin, D.S. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris. J. Clin. Microbiol. 2017, 55, 2445–2452. [Google Scholar] [CrossRef] [PubMed]
- Leach, L.; Zhu, Y.; Chaturvedi, S. Development and validation of a real-time PCR assay for rapid detection of Candida auris from surveillance samples. J. Clin. Microbiol. 2018, 56, e01223-17. [Google Scholar] [CrossRef] [PubMed]
- Sexton, D.J.; Kordalewska, M.; Bentz, M.L.; Welsh, R.M.; Perlin, D.S.; Litvintseva, A.P. Direct detection of emergent fungal pathogen Candida auris in clinical skin swabs by SYBR Green-Based Quantitative PCR Assay. J. Clin. Microbiol. 2018, 56, e01337-18. [Google Scholar] [CrossRef]
- Sexton, D.J.; Bentz, M.L.; Welsh, R.M.; Litvintseva, A.P. Evaluation of a new T2 Magnetic Resonance assay for rapid detection of emergent fungal pathogen Candida auris on clinical skin swab samples. Mycoses 2018, 61, 786–790. [Google Scholar] [CrossRef]
- U.S.A Centers for Disease Control and Prevention (CDC). Candida auris Antifungal Susceptibility Testing and Interpretation. Available online: https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html (accessed on 24 December 2024).
- Kean, R.; Delaney, C.; Sherry, L.; Borman, A.; Johnson, E.M.; Richardson, M.D.; Rautemaa-Richardson, R.; Williams, C.; Ramage, G. Transcriptome assembly and profiling of Candida auris reveals novel insights into biofilm-mediated resistance. mSphere 2018, 3, e00334-18. [Google Scholar] [CrossRef]
- Stathi, A.; Loukou, I.; Kirikou, H.; Petrocheilou, A.; Moustaki, M.; Velegraki, A.; Zachariadou, L. Isolation of Candida auris from cystic fibrosis patient, Greece, April 2019. Eurosurveillance 2019, 24, 1900400. [Google Scholar] [CrossRef]
- Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. [Google Scholar] [CrossRef] [PubMed]
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs for Antifungal Agents, Version 11.0. 2024. Available online: http://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals/ (accessed on 4 February 2025).
- Politi, L. The European Programme for Intervention Epidemiology Training (EPIET), 2021 Cohort National Public Health Organization (NPHO); Greece European Centre for Disease Prevention and Control: Athens, Greece, 2023. [Google Scholar]
- Katsiari, M.; Mavroidi, A.; Kesesidis, N.; Palla, E.; Zourla, K.; Ntorlis, K.; Konstantinidis, K.; Laskou, M.; Strigklis, K.; Sakkalis, A.; et al. Emergence of Clonally-Related South Asian Clade I Clinical Isolates of Candida auris in a Greek COVID-19 Intensive Care Unit. J. Fungi 2023, 9, 243. [Google Scholar] [CrossRef]
- Long, B.; Lacy, A.J.; Koyfman, A.; Liang, S.Y. Candida auris: A focused review for emergency clinicians. Am. J. Emerg. Med. 2024, 84, 162–167. [Google Scholar] [CrossRef]
- Dennis, E.K.; Chaturvedi, S.; Chaturvedi, V. So Many Diagnostic Tests, So Little Time: Review and Preview of Candida auris Testing in Clinical and Public Health Laboratories. Front. Microbiol. 2021, 12, 757835. [Google Scholar] [CrossRef]
- Chowdhary, A.; Tarai, B.; Singh, A.; Sharma, A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerg. Infect. Dis. 2020, 26, 2694–2696. [Google Scholar] [CrossRef]
- Villanueva-Lozano, H.; Treviño-Rangel, R.d.J.; González, G.M.; Ramírez-Elizondo, M.T.; Lara-Medrano, R.; Aleman-Bocanegra, M.C.; Guajardo-Lara, C.E.; Gaona-Chávez, N.; Castilleja-Leal, F.; Torre-Amione, G.; et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin. Microbiol. Infect. 2021, 27, 813–816. [Google Scholar] [CrossRef]
- Prestel, C.; Anderson, E.; Forsberg, K.; Lyman, M.; de Perio, M.A.; Kuhar, D.; Edwards, K.; Rivera, M.; Shugart, A.; Walters, M.; et al. Candida auris outbreak in a COVID-19 specialty care unit—Florida, July–August 2020. Morb. Mortal. Wkly. Rep. 2021, 70, 56–57. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez, J.Y.; Le Pape, P.; Lopez, O.; Esquea, K.; Labiosa, A.L.; Alvarez-Moreno, C. Candida auris: A latent threat to critically ill patients with coronavirus disease 2019. Clin. Infect. Dis. 2021, 73, e2836–e2837. [Google Scholar] [CrossRef]
- Horton, M.V.; Johnson, C.J.; Kernien, J.F.; Patel, T.D.; Lam, B.C.; Cheong, J.Z.A.; Meudt, J.J.; Shanmuganayagam, D.; Kalan, L.R.; Nett, J.E. Candida auris forms high-burden biofilms in skin niche conditions and on porcine skin. mSphere 2020, 5, e00910-19. [Google Scholar] [CrossRef] [PubMed]
- Kean, R.; McKloud, E.; Townsend, E.M.; Sherry, L.; Delaney, C.; Jones, B.L.; Williams, C.; Ramage, G. The comparative efficacy of antiseptics against Candida auris biofilms. Int. J. Antimicrob. Agents 2018, 52, 673–677. [Google Scholar] [CrossRef] [PubMed]
- Schelenz, S.; Hagen, F.; Rhodes, J.L.; Abdolrasouli, A.; Chowdhary, A.; Hall, A.; Ryan, L.; Shackleton, J.; Trimlett, R.; Meis, J.F.; et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob. Resist. Infect. Control 2016, 5, 35. [Google Scholar] [CrossRef]
- Yadav, A.; Singh, A.; Wang, Y.; Hi van Haren, M.; Singh, A.; de Groot, T.; Meis, J.F.; Xu, J.; Chowdhary, A. Colonisation and transmission dynamics of Candida auris among chronic respiratory diseases patients hospitalised in a Chest Hospital, Delhi, India: A comparative analysis of whole genome sequencing and microsatellite typing. J. Fungi 2021, 7, 81. [Google Scholar] [CrossRef]
- Pandya, N.; Cag, Y.; Pandak, N.; Pekok, A.U.; Poojary, A.; Ayoade, F.; Fasciana, T.; Giammanco, A.; Caskurlu, H.; Rajani, D.P.; et al. International multicentre study of Candida auris infections. J. Fungi 2021, 7, 878. [Google Scholar] [CrossRef]
- Forsberg, K.; Woodworth, K.; Walters, M.; Berkow, E.L.; Jackson, B.; Chiller, T.; Vallabhaneni, S. Candida auris: The recent emergence of a multidrug-resistant fungal pathogen. Med. Mycol. 2019, 57, 1–12. [Google Scholar] [CrossRef]
- Biran, R.; Cohen, R.; Finn, T.; Brosh-Nissimov, T.; Rahav, G.; Yahav, D.; Amit, S.; Shachor-Meyouhas, Y.; Atamna, A.; Bishara, J.; et al. Nationwide outbreak of Candida auris infections driven by COVID-19 hospitalizations, Israel, 2021–2022. Emerg. Infect. Dis. 2023, 29, 1297–1301. [Google Scholar] [CrossRef] [PubMed]
- Shastri, P.S.; Shankarnarayan, S.A.; Oberoi, J.; Rudramurthy, S.M.; Wattal, C.; Chakrabarti, A. Candida auris candidaemia in an intensive care unit-prospective observational study to evaluate epidemiology, risk factors, and outcome. J. Crit. Care 2020, 57, 42–48. [Google Scholar] [CrossRef] [PubMed]
- Kenters, N.; Kiernan, M.; Chowdhary, A.; Denning, D.W.; Pemán, J.; Saris, K.; Schelenz, S.; Tartari, E.; Widmer, A.; Meis, J.F.; et al. Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting. Int. J. Antimicrob. Agents 2019, 54, 400–406. [Google Scholar] [CrossRef]
- Garcia-Bustos, V.; Salavert, M.; Ruiz-Gaitán, A.C.; Cabanero-Navalon, M.D.; Sigona-Giangreco, I.A.; Pemán, J. A clinical predictive model of candidaemia by Candida auris in previously colonized critically ill patients. Clin. Microbiol. Infect. 2020, 26, 1507–1513. [Google Scholar] [CrossRef]
- Briano, F.; Magnasco, L.; Sepulcri, C.; Dettori, S.; Dentone, C.; Mikulska, M.; Ball, L.; Vena, A.; Robba, C.; Patroniti, N.; et al. Candida auris candidemia in critically ill, colonized patients: Cumulative incidence and risk factors. Infect. Dis. Ther. 2022, 11, 1149–1160. [Google Scholar] [CrossRef]
- Sayeed, M.A.; Farooqi, J.; Jabeen, K.; Awan, S.; Mahmood, S.F. Clinical spectrum and factors impacting outcome of Candida auris: A single center study from Pakistan. BMC Infect. Dis. 2019, 19, 384. [Google Scholar] [CrossRef]
- Cortegiani, A.; Misseri, G.; Fasciana, T.; Giammanco, A.; Giarratano, A.; Chowdhary, A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J. Intensive Care 2018, 6, 69. [Google Scholar] [CrossRef]
- Burrack, L.S.; Todd, R.T.; Soisangwan, N.; Wiederhold, N.P.; Selmecki, A. Genomic diversity across Candida auris clinical isolates shapes rapid development of antifungal resistance in vitro and in vivo. mBio 2022, 13, e00842-22. [Google Scholar] [CrossRef] [PubMed]
- Mulet-Bayona, J.V.; Salvador-Garcia, C.; Tormo-Palop, N.; Gimeno-Cardona, C. Recurrent candidemia and isolation of echinocandin-resistant Candida auris in a patient with a long-term central catheter. Enferm. Infecc. Microbiol. Clin. (Engl. Ed.) 2022, 40, 334–335. [Google Scholar] [CrossRef]
- Biagi, M.J.; Wiederhold, N.P.; Gibas, C.; Wickes, B.L.; Lozano, V.; Bleasdale, S.C.; Danziger, L. Development of high-level echinocandin resistance in a patient with recurrent Candida auris candidemia secondary to chronic candiduria. Open Forum Infect. Dis. 2019, 6, ofz262. [Google Scholar] [CrossRef]
- Proctor, D.M.; Drummond, R.A.; Lionakis, M.S.; Segre, J.A. One population, multiple lifestyles: Commensalism and pathogenesis in the human mycobiome. Cell Host Microbe 2023, 31, 539–553. [Google Scholar] [CrossRef]
- Caballero, U.; Kim, S.; Eraso, E.; Quindós, G.; Vozmediano, V.; Schmidt, S.; Jauregizar, N. In vitro synergistic interactions of isavuconazole and echinocandins against Candida auris. Antibiotics 2021, 10, 355. [Google Scholar] [CrossRef] [PubMed]
- Jaggavarapu, S.; Burd, E.M.; Weiss, D.S. Micafungin and amphotericin b synergy against Candida auris. Lancet Microbe 2020, 1, e314–e315. [Google Scholar] [CrossRef] [PubMed]
- Ahmad, S.; Asadzadeh, M. Strategies to prevent transmission of Candida auris in healthcare settings. Curr. Fungal Infect. Rep. 2023, 17, 36–48. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Tian, S.; Han, X.; Chu, Y.; Wang, Q.; Zhou, B.; Shang, H. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infect. Dis. 2020, 20, 827. [Google Scholar] [CrossRef]
- Taori, S.K.; Khonyongwa, K.; Hayden, I.; Athukorala, G.D.A.; Letters, A.; Fife, A.; Desai, N.; Borman, A.M. Candida auris outbreak: Mortality, interventions and cost of sustaining control. J. Infect. 2019, 79, 601–611. [Google Scholar] [CrossRef]
- ECDC Rapid Risk Assessment. Candida Auris in Healthcare Settings-Europe. European Centre for Disease Prevention and Control; Stockholm. 2018. Available online: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Candida-auris-European-Union-countries.pdf (accessed on 20 August 2020).
- Tsay, S.; Kallen, A.; Jackson, B.R.; Chiller, T.M.; Vallabhaneni, S. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin. Infect. Dis. 2018, 66, 306–311. [Google Scholar] [CrossRef]
- Sabino, R.; Veríssimo, C.; Pereira, Á.A.; Antunes, F. Candida auris, an agent of hospital-associated outbreaks: Which challenging issues do we need to have in mind? Microorganisms 2020, 8, 181. [Google Scholar] [CrossRef]
Risk Factor | All Patients (n = 32) | Colonized Patients (n = 26) | Infected Patients (n = 6) | p-Value |
---|---|---|---|---|
Demographics | ||||
Gender | 21 males (65.6) 11 females (34.4) | 17 males (65.4) 9 females (34.6) | 4 males (66.7) 2 females (33.3) | 0.724 |
Age (years) (mean ± S.D.) | 68 ± 14 | 69 ± 13 | 61 ± 16 | 0.189 |
APACHE II score (mean ± S.D.) b | 17.4 ± 6.9 | 17.4 ± 6.3 | 17.3 ± 9.5 | 0.987 |
Initial diagnosis b | 23 medical (71.9) 9 surgical (28.1) | 18 medical (69.2) 8 surgical (30.8) | 5 medical (83.3) 1 surgical (16.7) | 0.648 |
Prior LOS in hospital (days) [median (IQR)] | 13 (3–27) | 14 (5–46) | 6 (3–10) | 0.154 |
Comorbidities | ||||
COVID-19 | 11 (34.4) | 9 (34.6) | 2 (33.3) | 0.679 |
Cardiovascular disease | 15 (46.9) | 14 (53.8) | 1 (16.7) | 0.178 |
Chronic pulmonary disease | 5 (15.6) | 4 (15.4) | 1 (16.7) | 0.585 |
Neuropsychiatric disorders | 13 (40.6) | 13 (50) | 0 | 0.059 |
Diabetes | 9 (28.1) | 6 (23.1) | 3 (50) | 0.314 |
Chronic renal failure | 2 (6.2) | 2 (7.7) | 0 | 0.815 |
Malignancy | 11 (34.4) | 7 (26.9) | 4 (66.7) | 0.148 |
Immunosuppression c | 5 (15.6) | 4 (15.4) | 1 (16.7) | 0.585 |
On isolation day—treatment-related factors | ||||
ICU day | 7 (1–21) | 2 (1–13) | 25 (19–54) | 0.005 |
Corticosteroids | 14 (43.75) | 9 (34.6) | 5 (83.3) | 0.064 |
Renal replacement therapy | 4 (12.5) | 2 (7.7) | 2 (33.3) | 0.15 |
Prior antifungal administration | 9 (28.1) | 8 (30.8) | 1 (16.7) | 0.648 |
Outcome data | ||||
ICU LOS (days) | 24 (13–45) | 20 (12–37) | 52 (44–100) | 0.003 |
Time elapsed between 1st isolation and ICU discharge (days) (mean ± S.D.) | 18 ± 14 | 14 ± 10 | 36 ± 16 | <0.001 |
ICU survival | 18 (56.2) | 15 (57.7) | 3 (50) | 1.0 |
Survival on the 28th day after ICU discharge | 11 (34.4) | 9 (34.6) | 2 (33.3) | 1.0 |
Number of Patient c | Gender | Type of Specimen Positive for Candida auris | APHB b | ANF | MIF | CAS | ISA | POS | VOR | ITZ | FCA |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | Female | Hip decubitus ulcer | 0.5 | 0.12 | 0.5 | 0.12 | 0.03 | 0.25 | 0.25 | 0.12 | 128 |
Urine | - | -- | - | - | - | - | - | - | - | ||
2 | Female | Urine (ureterostomy) | 1 | 0.5 | 0.5 | 1 | 0.03 | 0.5 | 8 | 1 | 256 |
3 | Female | Urine | 1 | 0.12 | 0.12 | 0.12 | 0.06 | 0.25 | 8 | 0.5 | >256 |
4 | Male | Blood | 0.5 | 0.12 | 0.12 | 0.5 | 0.03 | 0.25 | 0.5 | 0.25 | 256 |
5 | Female | Tracheal aspirates | 1 | 0.25 | 0.25 | 0.12 | 0.06 | 0.12 | 0.12 | 0.06 | 256 |
6 | Female | Blood | 1 | 0.5 | 0.25 | 0.5 | 0.03 | 0.5 | 8 | 0.5 | >256 |
Urine | 1 | 0.5 | 0.25 | 0.5 | 0.03 | 0.5 | 8 | 0.5 | >256 | ||
Tracheal aspirates | - | -- | - | - | - | - | - | - | - | ||
7 | Male | Urine | 0.5 | 0.25 | 0.25 | 0.5 | <0.008 | 0.03 | 0.05 | 0.12 | 128 |
8 | Male | Swab from axilla/groin | 1 | 0.06 | 0.06 | 0.12 | 0.06 | 0.06 | 0.25 | 0.12 | 128 |
Central venous catheter | 11 | 0.06 | 0.06 | 0.12 | 0.06 | 0.06 | 0.25 | 0.12 | 256 | ||
9 | Female | Swab from axilla/groin | 1 | 0.5 | 0.5 | 0.25 | 0.03 | 0.12 | 0.5 | 0.12 | 32 |
10 | Male | Swab from axilla/groin | 0.5 | 0.5 | 0.5 | 0.5 | 0.12 | 0.25 | 8 | 0.5 | 256 |
Urine | 1 | 0.5 | 0.5 | 0.5 | 0.12 | .25 | 8 | 0.5 | >256 | ||
11 | Female | Swab from axilla/groin | 1 | 0.12 | 0.12 | 0.5 | 0.03 | 0.06 | 0.5 | 0.12 | 128 |
12 | Male | Hip decubitus ulcer | 1 | 0.25 | 0.25 | 0.25 | 0.06 | 0.25 | 0.25 | 0.25 | 32 |
13 | Male | Swab from axilla/groin | 1 | 0.25 | 0.25 | 0.5 | 0.06 | 0.015 | 2 | 0.25 | 32 |
14 | Female | Blood | 1 | 0.5 | 0.5 | 1 | 0.06 | 0.25 | 8 | 0.5 | >256 |
Central venous catheter | 1 | 0.5 | 0.5 | 1 | 0.06 | 0.25 | 8 | 0.5 | >256 | ||
15 | Female | Swab from axilla/groin | 1 | 0.5 | 0.5 | 1 | 0.03 | 0.25 | 8 | 0.5 | >256 |
16 | Male | Swab from axilla/groin | 1 | 0.5 | 0.5 | 1 | 0.12 | 0.5 | 8 | 0.5 | >256 |
17 | Male | Swab from axilla/groin | 0.5 | 0.5 | 0.5 | 1 | 0.12 | 0.5 | 8 | 0.5 | >256 |
Tracheal aspirates | - | -- | - | - | - | - | - | - | - | ||
18 | Male | Tracheal aspirates | 1 | 0.5 | 0.25 | 0.5 | 0.06 | 0.06 | 1 | 0.25 | >256 |
19 | Female | Swab from axilla/groin | 1 | 0.25 | 0.25 | 0.25 | 0.015 | 0.12 | 2 | 0.25 | >256 |
Tracheal aspirates | - | -- | - | - | - | - | - | - | - | ||
20 | Male | Blood | 1 | 0.12 | 0.12 | 0.25 | 0.03 | 0.25 | 2 | 0.25 | >256 |
Swab from axilla/groin | - | -- | - | - | - | - | - | - | - | ||
21 | Male | Swab from axilla/groin | 1 | 0.12 | 0.12 | 0.25 | 0.03 | 0.06 | 1 | 0.12 | 128 |
22 | Male | Blood | 1 | 0.12 | 0.12 | 0.06 | 0.03 | 0.03 | 0.5 | 0.12 | 128 |
23 | Male | Swab from axilla/groin | 1 | 0.12 | 0.12 | 0.25 | 0.06 | 0.06 | 0.5 | 0.25 | 128 |
Leg decubitus ulcer | - | -- | - | - | - | - | - | - | - | ||
24 | Male | Swab from axilla/groin | 0.5 | 0.12 | 0.03 | 0.12 | <0.008 | <0.008 | 0.12 | 0.03 | 64 |
25 | Male | Swab from axilla/groin | 1 | 0.12 | 0.012 | 0.5 | 0.06 | 0.06 | 0.5 | 0.12 | >256 |
26 | Male | Swab from axilla/groin | 1 | 0.12 | 0.03 | 0.5 | 0.06 | 0.06 | 0.5 | 0.25 | 128 |
27 | Female | Swab from axilla/groin | 0.5 | 0.12 | 0.12 | 0.5 | 0.015 | 0.03 | 0.25 | 0.12 | 128 |
Urine | - | -- | - | - | - | - | - | - | - | ||
28 | Male | Swab from axilla/groin | 1 | 0.5 | 0.12 | 0.5 | 0.03 | 0.06 | 0.5 | 0.12 | 64 |
Tracheal aspirates | - | -- | - | - | - | - | - | - | - | ||
29 | Male | Blood | 1 | 0.12 | 0.03 | 0.5 | 0.015 | 0.03 | 0.5 | 0.12 | 128 |
Central venous catheter | 1 | 0.12 | 0.03 | 0.5 | 0.015 | 0.03 | 0.5 | 0.12 | 128 | ||
30 | Male | Swab from axilla/groin | 0.5 | 0.12 | 0.12 | 0.25 | 0.03 | 0.03 | 0.5 | 0.25 | 128 |
Urine | - | -- | - | - | - | - | - | - | - | ||
Tracheal aspirates | - | -- | - | - | - | - | - | - | - | ||
31 | Male | Urine | 0.5 | 0.06 | 0.12 | 0.12 | 0.03 | 0.06 | 0.25 | 0.25 | 256 |
32 | Male | Swab from axilla/groin | - | -- | - | - | - | - | - | - | - |
Tracheal aspirates | 1 | 0.12 | 0.12 | 0.25 | 0.015 | 0.03 | 1 | 0.5 | 64 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Katsiari, M.; Nikolaou, C.; Palla, E.; Theodoridou, K.; Tsakris, A.; Vrioni, G. Impact of Candida auris on Critically Ill Patients: A Three-Year Observational Study in a Greek Intensive Care Unit. Pathogens 2025, 14, 328. https://doi.org/10.3390/pathogens14040328
Katsiari M, Nikolaou C, Palla E, Theodoridou K, Tsakris A, Vrioni G. Impact of Candida auris on Critically Ill Patients: A Three-Year Observational Study in a Greek Intensive Care Unit. Pathogens. 2025; 14(4):328. https://doi.org/10.3390/pathogens14040328
Chicago/Turabian StyleKatsiari, Maria, Charikleia Nikolaou, Eleftheria Palla, Kalliopi Theodoridou, Athanasios Tsakris, and Georgia Vrioni. 2025. "Impact of Candida auris on Critically Ill Patients: A Three-Year Observational Study in a Greek Intensive Care Unit" Pathogens 14, no. 4: 328. https://doi.org/10.3390/pathogens14040328
APA StyleKatsiari, M., Nikolaou, C., Palla, E., Theodoridou, K., Tsakris, A., & Vrioni, G. (2025). Impact of Candida auris on Critically Ill Patients: A Three-Year Observational Study in a Greek Intensive Care Unit. Pathogens, 14(4), 328. https://doi.org/10.3390/pathogens14040328